Good Ivermectin data being manipulated or ignored by Media and Universities

Ivermectin review by pro vaccine Dr John Campbell 220,000 patients over 6 months in 2020 shows when adjusted for residual variables, reduction in mortality or hospitalization rate was about 70%

Description Ivermectin in Africa and Brazil

Mar 14 2022 Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching (Brazil)

https://www.cureus.com/articles/82162-ivermectin-prophylaxis-used-for-covid-19-a-citywide-prospective-observational-study-of-223128-subjects-using-propensity-score-matching

Background

Ivermectin has demonstrated different mechanisms of action, coronavirus infection and COVID-19-related comorbidities.

Prophylaxis combined with the known safety profile of ivermectin

Study to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.

Prospective, July 2020 and December 2020

Inviting the entire population of Itajaí to a medical visit to enroll in the program,

ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.

Study analysis consisted of comparing ivermectin users with non-users using cohorts

Results

223,128 citizens of Itajaí considered

159,561 included in the analysis

113,845 (71.3%) regular ivermectin users

45,716 (23.3%) non-users

Of these

4,311 ivermectin users were infected, (3.7% infection rate)

3,034 non-users (6.6% infection rate)

A 44% reduction in COVID-19 infection rate

Risk ratio (RR), 0.56

The regular use of ivermectin led to a 68% reduction in COVID-19 mortality

Deaths

25 (0.8%) deaths in the ivermectin group

79 (2.6%) among ivermectin non-users

RR, 0.32

p less than 0.0001

When adjusted for residual variables, reduction in mortality rate was 70%

There was a 56% reduction in hospitalization rate

44 in the ivermectin group

99 in non ivermectin users

After adjustment for residual variables, reduction in hospitalization rate was 67%

p less than 0.0001

Conclusion

In this large study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.

https://m.youtube.com/watch?v=Gz4adJXLHgA

https://www.pennlive.com/coronavirus/2022/03/ivermectin-shows-no-benefit-in-treating-covid-19-new-study-finds.html

The results below in a small test show that about 3x more died in the non ivermectin group than with those taking ivermectin plus ivermectin had a range of other favorable outcomes in other serious Covid outcomes - yet the result is headlined ivermectin shows no benefit and no reporting of big patient study of 220,000 people in one city showing 70% reduction in mortality.

The study found that 52 of 241 patients in the ivermectin group and 43 of 249 patients in the control group progressed to severe illness.

Among the other findings: — 4 patients in the ivermectin group vs. 10 patients in the control group needed a ventilator; — 6 patients in the ivermectin group vs. 8 in the control group needed intensive care; — 3 patients in the ivermectin group vs. 10 in the control group died

https://www.pennlive.com/coronavirus/2022/03/ivermectin-shows-no-benefit-in-treating-covid-19-new-study-finds.html